OCUL Ocular Therapeutix Inc

Price (delayed)

$13.51

Market cap

$1.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$876.17M

Highlights
Ocular Therapeutix's gross margin has surged by 72% YoY and by 2.6% QoQ
Ocular Therapeutix's gross profit has increased by 30% QoQ
Ocular Therapeutix's quick ratio has surged by 71% YoY but it has decreased by 10% QoQ
The net income has declined by 44% year-on-year but it has increased by 16% since the previous quarter

Key stats

What are the main financial stats of OCUL
Market
Shares outstanding
76.29M
Market cap
$1.03B
Enterprise value
$876.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.32
Price to sales (P/S)
46.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.58
Earnings
Revenue
$22.14M
EBIT
-$124.19M
EBITDA
-$121.5M
Free cash flow
-$52.81M
Per share
EPS
-$2.13
Free cash flow per share
-$0.69
Book value per share
$1.1
Revenue per share
$0.29
TBVPS
$3.19
Balance sheet
Total assets
$243.04M
Total liabilities
$159.63M
Debt
$56.61M
Equity
$83.41M
Working capital
$200.7M
Liquidity
Debt to equity
0.68
Current ratio
8.31
Quick ratio
8.19
Net debt/EBITDA
1.27
Margins
EBITDA margin
-548.9%
Gross margin
90.3%
Net margin
-591.8%
Operating margin
-300.2%
Efficiency
Return on assets
-73.8%
Return on equity
-326%
Return on invested capital
-195.3%
Return on capital employed
-57.6%
Return on sales
-561%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUL stock price

How has the Ocular Therapeutix stock price performed over time
Intraday
0.15%
1 week
-6.51%
1 month
-3.43%
1 year
51.46%
YTD
-34.73%
QTD
-17.67%

Financial performance

How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$22.14M
Gross profit
$19.98M
Operating income
-$66.46M
Net income
-$131M
Gross margin
90.3%
Net margin
-591.8%
Ocular Therapeutix's operating margin has soared by 77% YoY and by 17% from the previous quarter
Ocular Therapeutix's gross margin has surged by 72% YoY and by 2.6% QoQ
The net margin has soared by 59% YoY and by 34% from the previous quarter
The net income has declined by 44% year-on-year but it has increased by 16% since the previous quarter

Growth

What is Ocular Therapeutix's growth rate over time

Valuation

What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
12.32
P/S
46.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.58
The company's EPS rose by 17% QoQ but it fell by 11% YoY
The equity is up by 10% since the previous quarter
The stock's P/S is 46% below its 5-year quarterly average of 85.8 and 20% below its last 4 quarters average of 58.3
The revenue has grown by 27% from the previous quarter

Efficiency

How efficient is Ocular Therapeutix business performance
Ocular Therapeutix's return on equity has surged by 95% YoY and by 65% QoQ
OCUL's return on invested capital has dropped by 63% year-on-year but it is up by 13% since the previous quarter
The company's return on sales has surged by 58% YoY and by 34% QoQ
The return on assets has grown by 36% since the previous quarter and by 33% year-on-year

Dividends

What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUL.

Financial health

How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets is 52% higher than its total liabilities
Ocular Therapeutix's total liabilities has soared by 91% YoY but it has decreased by 14% from the previous quarter
Ocular Therapeutix's quick ratio has surged by 71% YoY but it has decreased by 10% QoQ
The debt is 32% less than the equity
The company's debt to equity has surged by 112% YoY but it fell by 12% QoQ
The equity is up by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.